Background. Current guidelines suggest consideration of sentinel lymph node biopsy (SLNB) for patients with ductal carcinoma in situ (DCIS) undergoing mastectomy. Our objective was to identify factors influencing the utilization of SLNB in this population. Methods. We used the Surveillance Epidemiology and End Results database to identify all women with breast DCIS treated with mastectomy from 2000 to 2008. We excluded patients without histologic confirmation, those diagnosed at autopsy, those who had axillary lymph node dissections performed without a preceding SLNB, and those for whom the status of SLNB was unknown. We used multivariate logistic regression reporting odds ratios (OR) and 95 % confidence intervals (CI) to evaluate the relationship of patient-and tumor-related factors to the likelihood of undergoing SLNB. Conclusions. SLNB is increasingly utilized in patients undergoing mastectomy for DCIS, but disparities in usage remain. Efforts at improving rates of SLNB in this population are warranted.
Increasing breast cancer awareness and screening mammography have resulted in an increase in the incidence of ductal carcinoma in situ (DCIS). 1 Whereas both breast conservation therapy and mastectomy are options for the surgical treatment of DCIS, there is recent trend among patients favoring mastectomy. 2, 3 Sentinel lymph node biopsy (SLNB) is an established, minimally invasive method of lymph node assessment in women with clinically node-negative breast cancer who undergo mastectomy. By definition, DCIS lacks an invasive component and therefore has no potential to metastasize to lymph nodes or elsewhere. However, approximately 10-38 % of patients diagnosed with DCIS on core-needle biopsy harbor occult invasive cancer that is only detected on final pathologic examination. [4] [5] [6] [7] [8] Past and current guidelines suggest consideration of SLNB in patients undergoing mastectomy for DCIS (level 2A evidence). 9, 10 The rationale for this is based on the observation that mastectomy disrupts breast lymphatic drainage patterns enough to preclude SLNB after mastectomy should invasive cancer be incidentally found on final pathology. Our objective was to determine how often SLNB is used in women undergoing mastectomy for DCIS and to identify patient, tumor, and geographic factors that influence utilization of SLNB in these women.
METHODS
We used the Surveillance, Epidemiology, and End Results (SEER) database to identify all woman treated by mastectomy for DCIS of the breast diagnosed from 2000 through 2008. All cases represent patients with pure DCIS diagnosed on final pathology. SEER collects cancer incidence, prevalence, and survival data from 17 populationbased cancer registries representing 28 % of the U.S. population. SEER furthermore provides information on patient demographics, primary tumor site, tumor morphology, stage at diagnosis, and first course of treatment. The population reporting to SEER is comparable to the general population with respect to measures of poverty and education but is slightly more urban than the general U.S. population. Current SEER registries consist of the states of Connecticut, Hawaii, Iowa, Kentucky, Louisiana, New Jersey, New Mexico, and Utah; the metropolitan areas of Atlanta, Detroit, San Francisco-Oakland, Seattle-Puget Sound, and San JoseMonterey; and the Alaska Native Tumor Registry, rural Georgia, Greater California, and Los Angeles County.
Patients were identified as having had a SLNB only if this was specifically coded. All tumor size measurements reported represent an in situ component only; patients with invasive breast cancer, synchronous DCIS, and prior breast malignancy were excluded. We also excluded patients without histologic confirmation, those diagnosed at autopsy, those who had axillary lymph node dissections (ALND) performed for axillary staging without a preceding SLNB, and those for whom the status of SLNB was unknown.
Multivariate logistic regression evaluated the relationship between tumor-and patient-related factors on the likelihood of undergoing SLNB. Covariates evaluated included patient age (Bmean age or [mean age), race/ ethnicity (white, black, Asian, Hispanic, Native American, unknown), year of diagnosis (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) , tumor grade (low, intermediate, high, unknown), size of DCIS (\2, 2-5, [5 cm, unknown), estrogen receptor (ER) status (positive, negative, borderline, unknown), and regional location of SEER registry (west, midwest, northeast, south). We determined whether patients' DCIS represented their only known malignancy or if they had additional non-breast cancers before their diagnosis of DCIS. An additional multivariate model was constructed that differed only in its inclusion of patients for whom DCIS was their only reported malignancy. To account for the impact of recent guidelines on disparities in utilization for SLNB, a third multivariate model was constructed including only patients diagnosed between 2006 and 2008. All models included women with incomplete data regarding size, grade, ER status, and race, because these predictors may not necessarily be available to all surgeons at the time of surgery for DCIS.
We used odds ratios (OR) and 95 % confidence intervals (CI) to identify significant associations. All statistical analyses were done using STAT 11 (College Station, TX) and R version 2.14.1 (http://www.R-project.org). Because information in SEER contains deidentified patient data, this study was exempt from institutional review board approval.
RESULTS
A total of 20,177 woman met inclusion criteria. Table 1 depicts the patient-and tumor-related characteristics of the study cohort.
The mean age was 56 years, and the majority was white women (75 %) who resided in states incorporated into western SEER registries (58 %). The majority of patients had no prior history of malignancy (73 %), whereas 27 % of patients had a non-breast malignancy before the diagnosis of DCIS. Overall, 51 % of patients did not receive SLNB at the time of mastectomy. By contrast, of those for whom DCIS was their first or only primary tumor, 46 % did not receive SLNB. Among those who received a SLNB, 13 and 29 % had incomplete data regarding grade and size focus of DCIS, respectively. Among women with known DCIS grade, SLNB was performed more often for high-grade DCIS (58 %) followed by intermediate-grade (47 %), and low-grade (38 %; Fig. 1a) . Similarly, when stratified by DCIS size, a greater proportion of women with DCIS [ 5 cm (71 %) received a SLNB than women with DCIS between 2 and 5 cm (58 %) and women with DCIS that was \2 cm (45 %; Fig. 1b ). Hormone receptor status was not assessed or was unknown in 57-60 % of patients.
The proportion of SLNBs performed significantly increased with time disproportionate to the increase in the use of mastectomy for DCIS (Fig. 2) . Use of SLNB increased from 19 % of all mastectomies in the year 2000 to 70 % of all mastectomies in the year 2008. Table 2 depicts the results of the multivariate logistic regression model assessing the odds of undergoing SLNB for the entire patient cohort. Factors associated with increased odds of SLNB included: year of diagnosis, increasing DCIS grade and size, and eastern regional location. Factors associated with a decreased likelihood of receiving a SLNB included age older than 56 years, Asian or Hispanic race, and history of prior non-breast malignancy. We further looked at patterns of SLNB among patients without a prior history of malignancy (N = 14,699). Our findings in this limited model were unchanged, except that Hispanic ethnicity was no longer a significant predictor of receiving SLNB (Table 3) . Finally, we examined significant predictors of SLNB in a more contemporary model of patients who underwent mastectomy for DCIS between [2006] [2007] [2008] (N = 7,883). In this model, increasing DCIS grade and size, but not geographic location, continued to be associated with increased odds of undergoing SLNB, whereas patients older than 56 years, of Asian ethnicity, or with a history of prior malignancy remained less likely to receive SLNB.
DISCUSSION
Those who oppose SLNB at the time of mastectomy for DCIS cite the low rate (1-10 %) of lymph node metastasis in DCIS diagnosed by core needle biopsy, even among patients with high risk DCIS. 1, [11] [12] [13] However, the clinical significance of lymph node metastases in DCIS patients is unclear, because majority of these metastases are isolated tumor cells. Among 470 patients with DCIS undergoing SLNB, Moore et al. noted 47 cases (9 %) of metastasis. 14 However, true upstaging occurred in only 1.5 % of patients if all cases of isolated tumor were excluded. Moreover, Proponents of SLNB at the time of mastectomy argue that there is no other way to stage the lymph node basin reliably. If invasive breast cancer is identified after ER estrogen receptor; OR odds ratio; CI confidence interval mastectomy, an SLNB can no longer be performed reliably due to altered lymphatic drainage of the breast. 16 One must then decide between observation, which may lead to understaging and therefore undertreatment, or ALND, which is associated with significantly higher rates of morbidity than SLNB. 17 Studies have documented upstaging to invasive breast carcinoma in approximately 10-38 % of patients diagnosed with DCIS on core-needle biopsy.
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These studies prompted a major change to the 2008 NCCN guidelines, which previously did not recommend SLNB in patients undergoing mastectomy for DCIS. However, American Society of Clinical Oncology (ASCO) guidelines have recommend consideration of SLNB in these patients since 2005. The difference in timing of these recommendations may account for the low (51 %) overall observed rate of SLNB in women undergoing mastectomy as well as for the observed disparities in use associated with tumor-related (grade and size of DCIS focus) and nontumor-related factors (age, year of diagnosis, race/ethnicity, and geographic location). These disparities reflect the evolving understanding of the pathology of DCIS and the somewhat controversial nature of lymph node assessment in patients with DCIS. Both high grade and large DCIS size have been associated with increased risk of harboring invasive cancer, which may explain why patients with these characteristics were more likely to undergo SLNB at time of mastectomy in our study. 7, 18 Risk of invasive cancer also is increased with DCIS recurrence, which may explain why women without a prior primary tumor were less likely to undergo SLNB than women with a history of prior cancers.
Age-related, racial, and geographic disparities have been previously documented in women with invasive cancer undergoing SLNB. A study by Reeder-Hayes et al. [19] [20] [21] [22] using SEER to evaluate women with early-stage breast cancer found that black women and those older than age 80 years were less likely to undergo SLNB. Other studies have documented similar results. Interestingly, although we did observe similar age-related disparities in the use of SLNB, there was not such a disparity in blacks. Rather, a lower likelihood of SLNB was noted among Asian women. This may reflect the relatively larger growth in underserved Asian population. According to the 2010 United States Census, the Asian population increased by 43 % since the year 2000, whereas the African American population increased by only 12 %. Most of this growth was in the south and west, where the population increased by 13-15 % during the past decade compared with a 3 % increase in the northeast. This shifting in census may explain the geographic disparities that we observed and why they vary depending on the years studied. 20 A previous SEER analysis performed between 1998 and 2002 demonstrated that nearly 87 % of women who had mastectomy and lymph node assessment for DCIS had ALND, whereas only 13 % underwent SLNB. 23 Despite the low overall rate of SLNB in our study, we did see an increasing trend in its utilization, which was disproportionate to the overall increase in mastectomies during the past 5 years. This perhaps reflects the increasing acceptance of SLNB following the release of the 2005 ASCO guidelines advocating its use and continued divergence from the use of ALND.
Our study has several limitations inherent to the utilization of population-based data. Our patient population was limited because we excluded cases of DCIS before the year 2000. We chose these years because SEER did not start coding for SLNB until 1998, and we wanted to avoid early irregularities in coding that might have existed. Our data also could be subject to selection bias. Our patient population includes only patients with a diagnosis of DCIS on their final histopathology. Ideally, we would like to capture the entire cohort of patients who had DCIS diagnosed on initial core biopsy, including those that were subsequently diagnosed with invasive carcinoma at mastectomy. Our overall rate of utilization of SLNB might be higher if such patients were included in our cohort. Data completeness also could have influenced our data. SEER does not report information on patient preference, prior surgical or pathologic information, and pregnancy status, which may influence surgical decision making. This is especially important in the 27 % of women with additional non-breast tumor diagnoses. It is possible that these women were deemed higher risk for invasive malignancy based on previous treatment, such as chest wall radiation, which could influence use of SLNB. We included these women in our analysis, because SLNB would still be indicated in these women using current guidelines.
If trends continue and more women undergo mastectomy for DCIS, it is going to be important to identify disparities in care consistent with national consensus guidelines. This will allow specifically targeted patient education, physician training, and further research in these areas. We have demonstrated that although utilization of SLNB is increasing, it remained underutilized in older women of racial/ethnic minorities and those with low-risk DCIS. These potential factors that promote underutilization of SLNB are areas that can be addressed by further research or educational programs.
